In today’s briefing:
- AKM Industrial’s Offer Spread Risk/Reward
- Merger Arb Mondays – Yashili, Razer, 51job, Sezzle, Link, Uniti, Guodian, Jin Jiang
- Meituan (3690 HK): 4Q21, Strong Revenue and Promising Initiatives
- Akeso Biopharma Inc (9926.HK) – Caution Is Advised Until Sufficient Financing Is Secured
- Shangri-La Asia (69 HK): On a Clear Recovery Path
- JD.com (9618) Re Test of Low Sets up a Very Bullish 2H 2022
- Morning Views Asia: China Aoyuan Property, Guangzhou R&F Properties
AKM Industrial’s Offer Spread Risk/Reward
- AKM Industrial (1639 HK)’s privatisation offer from Alpha Luck and AKM Meadville of HK$1.8345 consists of a base offer (HK$1.82) and a final dividend (HK1.45 cents).
- Approval from the State Administration of Foreign Exchange is the remaining pre-condition. The Court hearing of the petition for the sanction of the scheme is set for 19 July.
- At last close and for a July end effective date, the gross and annualised spread to the total offer of HK$1.8345 is 3.6% and 11.2%, respectively.
Merger Arb Mondays – Yashili, Razer, 51job, Sezzle, Link, Uniti, Guodian, Jin Jiang
- We summarise the latest spreads and newsflow of merger arb situations covered by us across Hong Kong, Australia, New Zealand, Singapore and the US (Chinese ADRs only).
- This week, the highest gross spreads are Yashili International Holdings (1230 HK), Razer Inc (1337 HK), 51 Job Inc Adr (JOBS US), Sezzle Inc (SZL AU)
- Lowest gross spreads CIMIC Group Ltd (CIM AU), Z Energy Ltd (ZEL NZ), China Logistics Property Holdings (1589 HK), Virtus Health (VRT AU), Mapletree North Asia Commercial Trust (MAGIC SP)
Meituan (3690 HK): 4Q21, Strong Revenue and Promising Initiatives
- Meituan’s total revenue continued to rise strongly by 31% in 4Q21.
- Initiatives businesses are losing money, but two of them are in leading positions.
- We believe the stock has a 20% upside for this year.
Akeso Biopharma Inc (9926.HK) – Caution Is Advised Until Sufficient Financing Is Secured
- Akeso has a very high starting point, and was regarded as the leader of domestic second-tier biotech companies. However, in current unfavorable market sentiment, it’s necessary to re-examine the Company.
- In Akeso’s pipeline, there are some valuable and differentiated candidates, especially in the field of bispecific antibodies. Its R&D capability is also well recognized.
- However, due to the rich pipeline, related clinical trials will drain money fast. So, investors are advised to be cautious until Akeso has ensured sustainable and stable cash flow.
Shangri-La Asia (69 HK): On a Clear Recovery Path
- There is a strong recovery in Shangri-La Asia (69 HK) in 2H21 as its losses narrowed 36.4% HoH and by 57.5% YoY – hotels and investment properties are primary drivers.
- 1Q22 momentum is solid with occupancy outside of Hong Kong and mainland China saw good YoY rebound. In FY21, room rates in France, Australia and UK have surpassed 2018 levels.
- Refinancing for FY22 has almost completed, implying minimal liquidity risks. Trading at 76% discount to adjusted NAV of HK$25.44, the stock is way too cheap.
JD.com (9618) Re Test of Low Sets up a Very Bullish 2H 2022
- JD.com (9618) HK denotes formidable resistance at 260 that will induce a downside re test toward the low zone.
- High sell volumes on the decline followed by weak buy volumes on the recent rise makes for a vulnerable rise with risk of a hard giveback.
- Low re test/new low sets up a buy for a rally to 310/350 in Q3/Q4. Bullish macro A-B-C pullback sequence stands out.
Morning Views Asia: China Aoyuan Property, Guangzhou R&F Properties
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.
Before it’s here, it’s on Smartkarma